188 related articles for article (PubMed ID: 23935155)
1. The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States.
Messali A; Hay JW; Villacorta R
Neuro Oncol; 2013 Nov; 15(11):1532-42. PubMed ID: 23935155
[TBL] [Abstract][Full Text] [Related]
2. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany.
Waschke A; Arefian H; Walter J; Hartmann M; Maschmann J; Kalff R
J Neurooncol; 2018 Jun; 138(2):359-367. PubMed ID: 29468446
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme.
Uyl-de Groot CA; Stupp R; van der Bent M
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):235-41. PubMed ID: 19527095
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study.
Lamers LM; Stupp R; van den Bent MJ; Al MJ; Gorlia T; Wasserfallen JB; Mittmann N; Jin Seung S; Crott R; Uyl-de Groot CA;
Cancer; 2008 Mar; 112(6):1337-44. PubMed ID: 18213621
[TBL] [Abstract][Full Text] [Related]
6. Subgroup economic analysis for glioblastoma in a health resource-limited setting.
Wu B; Miao Y; Bai Y; Ye M; Xu Y; Chen H; Shen J; Qiu Y
PLoS One; 2012; 7(4):e34588. PubMed ID: 22511951
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme.
Martikainen JA; Kivioja A; Hallinen T; Vihinen P
Pharmacoeconomics; 2005; 23(8):803-15. PubMed ID: 16097842
[TBL] [Abstract][Full Text] [Related]
8. A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments.
Messali A; Villacorta R; Hay JW
Pharmacoeconomics; 2014 Dec; 32(12):1201-12. PubMed ID: 25085219
[TBL] [Abstract][Full Text] [Related]
9. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
Kovic B; Xie F
J Clin Oncol; 2015 Jul; 33(20):2296-302. PubMed ID: 26014296
[TBL] [Abstract][Full Text] [Related]
10. Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study.
Guzauskas GF; Pollom EL; Stieber VW; Wang BCM; Garrison LP
J Med Econ; 2019 Oct; 22(10):1006-1013. PubMed ID: 31050315
[No Abstract] [Full Text] [Related]
11. Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis.
Roussakow SV
BMJ Open; 2017 Nov; 7(11):e017387. PubMed ID: 29102988
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Stupp R; Mason WP; van den Bent MJ; Weller M; Fisher B; Taphoorn MJ; Belanger K; Brandes AA; Marosi C; Bogdahn U; Curschmann J; Janzer RC; Ludwin SK; Gorlia T; Allgeier A; Lacombe D; Cairncross JG; Eisenhauer E; Mirimanoff RO; ;
N Engl J Med; 2005 Mar; 352(10):987-96. PubMed ID: 15758009
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model.
Connock M; Auguste P; Dussart C; Guyotat J; Armoiry X
J Neurooncol; 2019 Jul; 143(3):605-611. PubMed ID: 31127507
[TBL] [Abstract][Full Text] [Related]
14. Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain.
Balañá C; Vaz MA; Lopez D; de la Peñas R; García-Bueno JM; Molina-Garrido MJ; Sepúlveda JM; Cano JM; Bugés C; Sanz SM; Arranz JL; Perez-Segura P; Rodriguez A; Martin JM; Benavides M; Gil M
Clin Transl Oncol; 2014 Mar; 16(3):273-9. PubMed ID: 23793813
[TBL] [Abstract][Full Text] [Related]
15. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients.
Minniti G; De Sanctis V; Muni R; Filippone F; Bozzao A; Valeriani M; Osti MF; De Paula U; Lanzetta G; Tombolini V; Maurizi Enrici R
J Neurooncol; 2008 May; 88(1):97-103. PubMed ID: 18250965
[TBL] [Abstract][Full Text] [Related]
17. The challenges of managing glioblastoma multiforme in developing countries: a trade-off between cost and quality of care.
Salem A; Hashem SA; Al-Rashdan A; Ezam N; Nour A; Alsharbaji A; Sughayer M; Mohamad I; Elyan M; Addas A; Al-Hussaini M; Almousa A
Hematol Oncol Stem Cell Ther; 2011; 4(3):116-20. PubMed ID: 21982884
[TBL] [Abstract][Full Text] [Related]
18. Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital.
Diebold G; Ducray F; Henaine AM; Frappaz D; Guyotat J; Cartalat-Carel S; Breant V; Fouquet A; Aulagner G; Honnorat J; Armoiry X
J Clin Pharm Ther; 2014 Dec; 39(6):642-8. PubMed ID: 25164371
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma.
Hsieh SY; Chan DT; Kam MK; Loong HH; Tsang WK; Poon DM; Ng SC; Poon WS
Hong Kong Med J; 2017 Dec; 23(6):594-8. PubMed ID: 28798282
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of concomitant radiotherapy in newly diagnosed glioblastoma multiforme: a multivariate analysis of 116 patients.
Okumus NO; Gursel B; Meydan D; Ozdemir O; Odabas E; Gonullu G
Ann Saudi Med; 2012; 32(3):250-5. PubMed ID: 22588435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]